Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Commentary|Articles|March 8, 2015
The Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes From SELECT
Author(s)Steven I. Sherman, MD
Steven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.
Advertisement
Clinical Pearls
Steven I. Sherman, MD, associate vice-provost for Clinical Research, professor and chair, Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial. The SELECT trial looked at lenvatinib versus placebo for the treatment of patients with relapsed/refractory differentiated thyroid cancer.
- One side effect of lenvatinib is that it alters the absorption of levothyroxine.
- It was anticipated that this effect would raise serum TSH levels. This could be significant because TSH can stimulate the growth of thyroid cancer.
- Though many patients developed increased TSH levels and needed increased dosing of thyroid hormone throughout the SELECT trial, the efficacy of lenvatinib was not affected.
Advertisement
Related to this article
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5